Novavax to Participate in National Vaccine Advisory Committee Meeting
- Bonds take a breather, Tencent tumbles
- Oil rises as markets expect further fall in inventories
- Tencent (TCEHY) Falls Sharply as State Media Describes Online Games as ‘Spiritual Opium’, Company Vows to Improve
- Clorox (CLX) Falls Sharply as COVID-19 Demand Wanes
- Antipodean currencies jump on central bank talk, US dollar subdued
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President, Research and Development, will participate in a session during the Department of Health and Human Services' National Vaccine Advisory Committee (NVAC) meeting, taking place virtually on June 17. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Session details are as follows:
Thursday, June 17, 2021
3:15 p.m. – 4:15 p.m. Eastern Time (ET)
Experiences in the Field: COVID-19 Vaccine Authorization and Beyond
Gregory M. Glenn, M.D., President, Research and Development
For more information or to register for the meeting, visit: https://www.hhs.gov/webforms/nvac/index.html.
About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
InvestorsNovavax, Inc.Erika Schultz | email@example.com
Solebury TroutAlexandra Roy | firstname.lastname@example.org
MediaAlison Chartan | 240-720-7804Laura Keenan | email@example.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-participate-in-national-vaccine-advisory-committee-meeting-301314763.html
SOURCE Novavax, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spaulding Ridge Secures OneStream Software's Platinum Partner Level Status
- Lument Closes $13.9 Million Bridge Loan for Acquisition of Texas Multifamily Community
- Sales Account Manager Sues Street Fleet For Alleged Sexual Harassment, Sex-Based Discrimination, Retaliation, And Breach Of Contract
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Related EntitiesTwitter, AdCom
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!